Novo Nordisk debuts Wegovy pill in first big game ad push
The spot anchors the company’s new “A New Way to Wegovy®” campaign, using humor to reshape weight management talks and challenge the idea that medication is “the easy way out.”
Novo Nordisk
Strive sues Eli Lilly and Novo Nordisk over GLP-1 access
Strive Compounding Pharmacy accuses drugmakers of anti-competitive actions to suppress lawful compounded GLP-1 medications and restrict patient choice.
FDA approves Novo Nordisk’s oral GLP-1 pill for weight loss
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
Novo Nordisk seeks FDA approval for 7.2 mg Wegovy dose
If accepted, the agency is expected to complete its review within one to two months.
Novo Nordisk cuts prices on Wegovy and Ozempic
The company reduced its prices following pressure from the Trump administration, which urged the company and competitor Eli Lilly to lower the cost of widely used weight-loss and diabetes drugs.
Trump strikes historic deal to cut drug prices
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
Canada authorizes Ozempic for kidney and heart protection in diabetes
Health Canada approved Ozempic to slow kidney disease and reduce heart deaths in type 2 diabetes, a first-of-its-kind approval that could help millions.
Novo Nordisk protects U.S. patients with legal wins against compounders
This includes ruling that permanently prohibits compounding pharmacy from selling illegitimate, knockoff Wegovy or Ozempic.
Novo Nordisk: FDA confirms end of Wegovy and Ozempic shortage
Novo Nordisk has increased manufacturing, running production facilities 24/7 to ensure steady shipments to wholesalers.